Bremelanotide (tentative brand name Rekynda; former developmental code name PT-141) is a peptide melanocortin receptor agonist which is under development by Palatin Technologies as a treatment
for female sexual dysfunction.
In January 2017, Palatin Technologies successfully completed two phase III clinical trials of bremelanotide for female sexual dysfunction.The New Drug Application of bremelanotide for female
sexual dysfunction was accepted by the FDA in June 2018 with a PDUFA date set for March 23, 2019.
